This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone showed strong anti-proliferation effect on ER-positive breast cancer MCF-7 cells in vitro, with an IC50 value of 4.41 uM. 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone can significantly down-regulate the expression of estrogen receptor-α (ER-α) and inhibit tumor growth in human breast cancer cell line BCAP-37 xenograft model.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone, CAS 1353676-65-9
5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone showed strong anti-proliferation effect on ER-positive breast cancer MCF-7 cells in vitro, with an IC50 value of 4.41 uM. 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone can significantly down-regulate the expression of estrogen receptor-α (ER-α) and inhibit tumor growth in human breast cancer cell line BCAP-37 xenograft model.
In vitro
We found that 5,7,3′,4′-tetrahydroxy-3-methoxy-8,5′-diprenylflavone showed potent anti-proliferation effects on ER-positive breast cancer MCF-7 cells in vitro (with an IC50 of 4.41 μM).[1]
In vivo
We found that 5,7,3′,4′-tetrahydroxy-3-methoxy-8,5′-diprenylflavone strongly down-regulated expression concentrations of estrogen receptor-α (ER-α) and were able to inhibit tumor growth in a xenograft model of the human breast cancer line BCAP-37 in vivo.[1]
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.